Empagliflozin Reversal of Arterial StiffnEss in Aging
Status:
RECRUITING
Trial end date:
2029-02-28
Target enrollment:
Participant gender:
Summary
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.